Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by TET2 is a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine. Additionally we are shipping TET2 Kits (1) and many more products for this protein.
Showing 10 out of 105 products:
Human Polyclonal TET2 Primary Antibody for IHC, ELISA - ABIN571057
Orr, Haffner, Nelson, Yegnasubramanian, Eberhart: Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. in PLoS ONE 2012
Human Polyclonal TET2 Primary Antibody for ELISA, IHC - ABIN4358584
Langemeijer, Kuiper, Berends, Knops, Aslanyan, Massop, Stevens-Linders, van Hoogen, van Kessel, Raymakers, Kamping, Verhoef, Verburgh, Hagemeijer, Vandenberghe, de Witte, van der Reijden, Jansen: Acquired mutations in TET2 are common in myelodysplastic syndromes. in Nature genetics 2009
Human Polyclonal TET2 Primary Antibody for EIA, WB - ABIN1450172
Tefferi, Levine, Lim, Abdel-Wahab, Lasho, Patel, Finke, Mullally, Li, Pardanani, Gilliland: Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. in Leukemia 2009
We confirm the negative prognostic impact imparted by ASXL1 (show ASXL1 Antibodies) mutations and suggest a favorable impact from TET2 mutations in the absence of ASXL1 (show ASXL1 Antibodies) mutations.
TET2 mutation occurred in a number of ATLL patients and was likely involved in their leukemogenesis.
TET2 expression is reduced in myelodysplatic syndrome/acute myeloid leukemia (show BCL11A Antibodies) patients, independently of mutational status.
CD34 (show CD34 Antibodies)(+) cells lowering expression of TET2 may play an oncogenic role on myeloid tumor and CD3 (show CD3 Antibodies)(+) T cells of myelodysplastic syndrome patients may be derived from the malignant clone.
inactivation of MLL3 and TET2 may play an important role in the tumorigenesis process of HTLV-I-induced acute adult T-cell leukemia.
5-methylcytosine (5-hmC) expression is decreased in esophageal squamous cell carcinoma tissues, and is associated with TET2 expression level; TET2 reduction and subsequent 5-hmC loss might affect ESCC development
Among 864 Dutch persons between 80 and 105.8 years of age, DNA sequence analysis of TET2 confirmed a high incidence of somatic mutations but no effect on 10-year survival.
Mutations in TET2 gene is associated with cutaneous T cell lymphoma and Sezary syndrome.
Data show that tet methylcytosine dioxygenase 2 TET2, isocitrate dehydrogenases 1/2 IDH1 (show IDH1 Antibodies)/IDH2 (show IDH2 Antibodies), serine/arginine-rich splicing factor 2 SRSF2 (show SRSF2 Antibodies), splicing factor 3b subunit 1 SF3B1 (show SF3B1 Antibodies), and ras proteins (KRAS/NRAS) are not conserved in dog mast Cell tumors.
Here, the authors reveal the methylcytosine dioxygenases TET1 (show TET1 Antibodies) and TET2 as active regulators of CTCF (show CTCF Antibodies)-mediated alternative splicing through conversion of 5-methylcytosine to its oxidation derivatives.
Reprogramming of spermatogonial stem cells from Tet1 (show TET1 Antibodies) and Tet2 double knockout mice however lacked demethylation of H19 (show NCKAP1 Antibodies) imprinting control regions.
The critical roles of TET1 (show TET1 Antibodies)/2 individually.
the stability of Foxp3 (show FOXP3 Antibodies) expression is markedly compromised in T reg (show KCNH2 Antibodies) cells from Tet2/Tet3 (show TET3 Antibodies) double-deficient mice.
Tet2 was responsible for increase in 5-hydroxymethylcytosine abundance after ischemic injury.
These results uncover the hypermethylation of DNA methylation (show HELLS Antibodies) canyons as the genomic key feature of Tet1 (show TET1 Antibodies)/Tet2 double-knockout mouse embryonic fibroblasts.
our results indicate that neuronal TET2 is positively involved in the regulation of cell survival.
UNG (show UNG Antibodies) might be involved in Tet-mediated DNA demethylation.
Findings indicate a novel type of hematological malignancy induced by tet oncogene 2 protein (Tet2) loss.
Both TET1 (show TET1 Antibodies) and TET2 are required for the repression of embryonic stem cells differentiation by PRDM14 (show PRDM14 Antibodies).
reduced expression leads to Foxp3 (show FOXP3 Antibodies) hypermethylation and impairment of Treg-cell-associated immune homeostasis
The protein encoded by this gene is a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine. The encoded protein is involved in myelopoiesis, and defects in this gene have been associated with several myeloproliferative disorders. Two variants encoding different isoforms have been found for this gene.
methylcytosine dioxygenase TET2
, probable methylcytosine dioxygenase TET2
, tet oncogene family member 2
, tet oncogene 2